News for Alumis Inc Registered shs

TipRanks 21h

Largest borrow rate increases among liquid names

TipRanks 4d

Largest borrow rate increases among liquid names

Seeking Alpha 5d

Alumis reports Q1 results

TipRanks 5d

Analysts’ Top Materials Picks: Alumis Inc. (ALMS), Axalta Coating Systems (AXTA)

TipRanks 5d

Alumis price target lowered to $25 from $26 at Oppenheimer

GlobeNewswire 5d

Alumis Reports First Quarter 2025 Financial Results and Highlights Recent Achievements

TipRanks 6d

Alumis reports Q1 net loss ($99M) vs. ($49.8M) last year

GlobeNewswire 7d

Alumis Stockholders Approve Merger with ACELYRIN

TipRanks 7d

Acelyrin stockholders approve merger agreement with Alumis

TipRanks 7d

Alumis stockholders approve merger agreement with Acelyrin

TipRanks 7d

Largest borrow rate increases among liquid names

TipRanks 19d

Acelyrin urges stockholders to vote for proposed merger with Alumis

Seeking Alpha 21d

Acelyrin gains as Trium Capital rebuffs M&A deal with Alumis

TipRanks 22d

Largest borrow rate increases among liquid names

TipRanks 28d

Analysts Offer Insights on Materials Companies: BASF SE (OtherBASFY) and Alumis Inc. (ALMS)

TipRanks 28d

Alumis price target lowered to $14 from $15 at H.C. Wainwright

GlobeNewswire 29d

Alumis and ACELYRIN Announce Amended Merger Agreement

Seeking Alpha 29d

Alumis, ACELYRIN amend proposed merger pact

TipRanks 29d

Alumis and Acelyrin sign ammended merger agreement

TipRanks 41d

new option listings on April 9th

GlobeNewswire 45d

Alumis and ACELYRIN File Joint Definitive Proxy Statement for Proposed Merger

TipRanks 56d

Alumis, Kaken Pharmaceutical enter ESK-001 collaboration and licensing agreement

Seeking Alpha 56d

Alumis rises on licensing deal with Japan’s Kaken

GlobeNewswire 56d

Alumis and Kaken Pharmaceutical Announce Collaboration and Licensing Agreement for ESK-001 in Dermatology in Japan

TipRanks 61d

Oppenheimer Sticks to Their Buy Rating for Alumis Inc. (ALMS)

TipRanks 61d

Alumis price target lowered to $15 from $19 at H.C. Wainwright

GlobeNewswire 62d

Alumis Reports Year End 2024 Financial Results and Highlights Recent Achievements

Seeking Alpha 62d

Alumis reports FY results

Seeking Alpha 68d

Acelyrin adopts poison pill as Tang Capital Partners raises stake

TipRanks 70d

Alumis Inc. (ALMS) Receives a Buy from H.C. Wainwright

GlobeNewswire 71d

Alumis to Present at Leerink's 2025 Global Healthcare Conference

TipRanks 71d

Alumis Inc. (ALMS) Receives a Buy from Oppenheimer

TipRanks 71d

Alumis announces data from the OLE of its Phase 2 STRIDE trial

GlobeNewswire 73d

Late-Breaking ESK-001 Phase 2 OLE Data Presented at 2025 AAD Annual Meeting Demonstrate Robust Clinical Responses Over 52-Weeks in Psoriasis

GlobeNewswire 77d

Alumis and ACELYRIN Reaffirm Strategic and Financial Rationale of Proposed Merger

Seeking Alpha 77d

Acelyrin falls as Acelyrin reaffirms deal commitment

TipRanks 77d

Acelyrin says Concentra indication not expected to result in superior proposal

TipRanks 77d

Acelyrin, Alumis reaffirm strategic, financial rationale of proposed merger

TipRanks 78d

Alumis Inc. (ALMS) Gets a Buy from Oppenheimer

GlobeNewswire 81d

Alumis Announces Late-Breaker Psoriasis Presentation of 52-week Phase 2 OLE Data for ESK-001 at 2025 American Academy of Dermatology Annual Meeting and Accelerated Topline Phase 3 Data Readout

GlobeNewswire 81d

Alumis Presents Additional Phase 1 Data at ACTRIMS Forum 2025 Supporting Potential of A-005 as First-in-Class CNS Penetrant TYK2 Inhibitor for Treatment of Neuroinflammatory and Neurodegenerative...

Seeking Alpha 88d

Acelyrin jumps 11% on acquisition offer from Concentra Biosciences

TipRanks 88d

Acelyrin confirms unsolicited indication of interest from Concentra Biosciences

TipRanks 98d

Analysts Offer Insights on Materials Companies: Alumis Inc. (ALMS) and Martin Marietta Materials (MLM)

GlobeNewswire 98d

Alumis to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference

TipRanks 99d

Oppenheimer Reaffirms Their Buy Rating on Alumis Inc. (ALMS)

TipRanks 99d

Alumis price target lowered to $26 from $32 at Oppenheimer

TipRanks 102d

Alumis price target lowered to $17 from $25 at Baird

Seeking Alpha 102d

Alumis and Acelyrin to merge in all-stock deal

TipRanks 102d

Alumis price target lowered to $19 from $26 at H.C. Wainwright

	
		OSZAR »